Catalpol, phosphodiesterase-4 inhibitors, and Kai Xin San have been demonstrated to improve CUMS-induced depression-like behavior in mice through NLRP3 activation (Wang Y. et al., 2021; Xie et al., 2021; Yu et al., 2021). Here, NLRP3 is linked to depressive symptom measurement.